Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCE-T02 in Advanced Solid Tumors
NCT06597721Phase 1Recruiting
- Sponsor
- Adcendo
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ADCE-T02 in solid tumor, pancreatic ductal adenocarcinoma (PDAC) and head and neck squamous cell carcinoma (HNSCC), sponsored by Adcendo. Primary endpoints: Maximum Tolerated Dose at 24 months, Recommended Expansion Phase Dose at 24 months and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
ADCE-T02
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06597721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597721.